Publications by authors named "P I Spuls"
The Eczema Area and Severity Index is an investigator-assessed instrument reporting clinical signs of atopic dermatitis. The instrument is extensively validated in both adult and paediatric populations and recommended as a core outcome measure to assess clinical signs by the Harmonising Outcome Measures for Eczema initiative in clinical trials and was recently recommended as an option to measure signs in clinical practice. Here, we review the validation of the instrument using standard assessment criteria, explore controversies and challenges to its universal applicability and highlight future electronic adaptations.
View Article and Find Full Text PDFArticle Synopsis
- * Current guidelines advise TB screening and preventive treatment prior to starting anti-TNF therapy, extending to other biologic therapies despite differing mechanisms of action.
- * New evidence suggests that some emerging therapies might not significantly raise TB reactivation risk, prompting calls to revise existing recommendations to better reflect individual patient risks and drug safety.
Background: Despite the widespread off-label use of methotrexate (MTX) for the treatment of atopic dermatitis (AD), there is limited high-quality evidence on dosing regimens and existing guidelines do not provide clear recommendations regarding dosing strategies.
Objective: The aim of this study was to achieve international consensus among AD experts to standardize the dosing regimen for MTX treatment in adults and children with AD.
Methods: An electronic Delphi (eDelphi) study was conducted from October 2021 to September 2022.
Article Synopsis
- - The study evaluates the efficacy and safety of the new biologic medication lebrikizumab for treating atopic dermatitis in comparison to other systemic treatments, using a systematic network meta-analysis of clinical trials.
- - Data was gathered from various medical databases, focusing on trials that assessed treatment effects for at least 8 weeks in patients with moderate to severe atopic dermatitis, with analysis conducted using random-effects Bayesian methods.
- - Key outcomes measured include the improvement in eczema severity (using scales like EASI and POEM), safety indicators such as serious adverse events, and the ability of participants to achieve significant improvements in their condition.